A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL

被引：0
|
作者：
Wierda, William G.
Balakrishnan, Kumudha [1 ]
Ferrajoli, Alessandra [2 ]
Kadie, Tapan
Cortes, Jorge E.
O'Brien, Susan [2 ]
Burger, Jan A. [2 ]
Tambaro, Francesco Paolo
Jalayer, Annette [1 ]
Lemer, Susan [2 ]
Keating, Michael J. [2 ]
Gandhi, Varsha [3 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1667 / 1667
页数：1
相关论文
共 50 条
  • [1] A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
    Jain, Nitin
    Balakrishnan, Kumudha
    Ferrajoli, Alessandra
    O'Brien, Susan M.
    Burger, Jan A.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Ayres, Mary L.
    Tambaro, Francesco Paolo
    Keating, Michael J.
    Gandhi, Varsha
    Wierda, William G.
    ONCOTARGET, 2017, 8 (13) : 22104 - 22112
  • [2] Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy
    Wierda, William G.
    Balakrishnan, Kumudha
    Ferrajoli, Alessandra
    O'Brien, Susan
    Burger, Jan A.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Tambaro, Francesco Paolo
    Jalayer, Annette
    Lerner, Susan
    Keating, Michael J.
    Gandhi, Varsha V.
    BLOOD, 2012, 120 (21)
  • [3] NCRI CLL201 trial: A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    Hillmen, Peter
    Pocock, Christopher
    Cohen, Dena
    Cocks, Kim
    Sayala, Hazem A.
    Rawstron, Andy
    Kennedy, Daniel B.
    Fegan, Christopher
    Milligan, Don W.
    Dearden, Claire
    Smith, Alexandra
    Lindop, Emma
    Pettitt, Andrew R.
    BLOOD, 2007, 110 (11) : 231A - 232A
  • [4] NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    Hillmen, P.
    Pocock, C.
    Cohen, D.
    Gregory, W.
    Cocks, K.
    Rawstron, A. C.
    Kennedy, D. B.
    Fegan, C.
    Milligan, D.
    Dearden, C.
    Smith, A.
    Lindop, E.
    Pettitt, A. R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 119 - 120
  • [5] A phase II trial of alemtizimab and rituximab in patients with previously untreated CLL
    Frankfurt, Olga
    Hamilton, Elizabeth
    Acharya, Simbi
    Duffey, Sara
    Raji, Adekunle
    Rosen, Steven T.
    BLOOD, 2007, 110 (11) : 612A - 613A
  • [6] Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute
    Flinn, Ian W.
    Cooper, R. Seth
    Thompson, Dana S.
    Waselenko, Jamie K.
    Reeves, James, Jr.
    Wise, Rudolph L.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [7] Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia (CLL).
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 360B - 361B
  • [8] A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
    Brown, J. R.
    Abramson, J.
    Hochberg, E.
    Mikler, E.
    Dalton, V.
    Werner, L.
    Reynolds, H.
    Thompson, C.
    McDonough, S. M.
    Kuang, Y.
    Ritz, J.
    Neuberg, D.
    Freedman, A. S.
    LEUKEMIA, 2010, 24 (11) : 1972 - 1975
  • [9] A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
    J R Brown
    J Abramson
    E Hochberg
    E Mikler
    V Dalton
    L Werner
    H Reynolds
    C Thompson
    S M McDonough
    Y Kuang
    J Ritz
    D Neuberg
    A S Freedman
    Leukemia, 2010, 24 : 1972 - 1975
  • [10] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
12345